PHARMAC announces new breast cancer medicines funding
PHARMAC has announced it will go out for funding proposals for fulvestrant (Faslodex) for breast cancer. PHARMAC also called for tenders for a CDK 4/6 inhibitor (palbociclib (Ibrance) or ribociclib (Kisqali)). Both are needed to extend the lives of women with advanced hormone-receptor (HR) positive HER2 negative breast cancer; 61% of women have this subtype of breast cancer and could benefit from these medicines.
Date published
Link to original
Publisher
